ExSight Ventures

Horizon Surgical Systems is focused on developing advanced technologies for microsurgery, particularly in the realm of ophthalmology. The company is creating a novel, AI-driven surgical robotic system that integrates robotics, medical imaging, and artificial intelligence. This innovative approach aims to enhance the precision and effectiveness of microsurgical procedures, ultimately improving patient outcomes. By actively engaging in research and development, Horizon Surgical Systems seeks to push the boundaries of microsurgery, addressing the evolving needs of healthcare professionals and patients alike.

ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

Re-Vana Therapeutics Ltd is a company based in Belfast, United Kingdom, specializing in ocular pharmaceuticals and drug delivery systems. Founded in 2016, it focuses on developing biodegradable drug delivery platforms that target chronic eye diseases, including age-related macular degeneration, diabetic retinopathy, glaucoma, and uveitis. The company offers two primary product platforms: OcuLief, designed for the long-term release of treatments for age-related macular degeneration and diabetic retinopathy, and EyeLief, aimed at delivering therapeutics for glaucoma and retinal diseases. These platforms utilize FDA-approved polymers and enable the controlled release of a variety of therapeutic molecules over periods ranging from one week to a year. Re-Vana’s approach enhances patient compliance by minimizing pain and the frequency of treatments, while also aiming to reduce side effects and healthcare costs.

Valitor, Inc. is a biotechnology company founded in 2010 and based in Berkeley, California. The company specializes in developing advanced, protein-based drugs through innovative methods that enhance therapeutic proteins' pharmacokinetics, target specificity, and bioactivity. Valitor's technology platform is versatile, enabling improvements in the pharmacological properties of various existing and emerging protein drugs. The company has established development pipelines in dermatology, ophthalmology, and orthopedics, showcasing its capabilities in creating novel drug products tailored to specific medical needs.

DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics for patients with rare and chronic diseases. The company specializes in RNA-based therapeutics, utilizing a delivery technology platform that enhances the distribution of nucleic acid drugs to various tissues and organ systems beyond the liver. This innovative approach addresses limitations associated with previous-generation RNA delivery methods, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's products target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017 and based in San Diego, California, DTx Pharma aims to provide personalized treatment options across multiple therapeutic areas.

ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

Re-Vana Therapeutics Ltd is a company based in Belfast, United Kingdom, specializing in ocular pharmaceuticals and drug delivery systems. Founded in 2016, it focuses on developing biodegradable drug delivery platforms that target chronic eye diseases, including age-related macular degeneration, diabetic retinopathy, glaucoma, and uveitis. The company offers two primary product platforms: OcuLief, designed for the long-term release of treatments for age-related macular degeneration and diabetic retinopathy, and EyeLief, aimed at delivering therapeutics for glaucoma and retinal diseases. These platforms utilize FDA-approved polymers and enable the controlled release of a variety of therapeutic molecules over periods ranging from one week to a year. Re-Vana’s approach enhances patient compliance by minimizing pain and the frequency of treatments, while also aiming to reduce side effects and healthcare costs.

DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics for patients with rare and chronic diseases. The company specializes in RNA-based therapeutics, utilizing a delivery technology platform that enhances the distribution of nucleic acid drugs to various tissues and organ systems beyond the liver. This innovative approach addresses limitations associated with previous-generation RNA delivery methods, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's products target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017 and based in San Diego, California, DTx Pharma aims to provide personalized treatment options across multiple therapeutic areas.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative treatments for endothelial cell-mediated diseases, particularly focusing on corneal conditions such as Fuchs dystrophy. Utilizing its engineered fibroblast growth factor-1 (FGF-1) technology platform, Trefoil aims to create first-in-class regenerative pharmacologic therapies to address serious ophthalmic diseases that can lead to preventable blindness. The company is currently advancing a topical eye drop formulation, TTHX1114, designed to treat ulcerative conditions affecting the cornea, which can result in corneal scarring and significant vision loss. With a management team possessing over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil is committed to improving human health through protein-engineered therapies. The company has gained recognition within the biopharmaceutical community, receiving accolades from programs such as the CONNECT Springboard business plan competition and the Southeast Biotechnology Early Company Competition.

ONL Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics to protect and improve vision in patients with retinal diseases and conditions. Founded in 2006 and headquartered in Ann Arbor, Michigan, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway. Its drug programs aim to safeguard photoreceptors, thereby enhancing outcomes for patients undergoing surgeries related to retinal detachment and other serious vision-threatening issues. Through its research and development efforts, ONL Therapeutics seeks to provide effective solutions for preserving sight and improving the quality of life for individuals affected by these conditions.

LensGen, Inc. is an ophthalmic medical device company based in Irvine, California, that focuses on developing innovative solutions for presbyopia and cataracts. Founded in 2011, the company has created a biomimetic, curvature-changing intraocular lens designed to mimic the natural human lens. This lens, known as Juvene™, utilizes the eye's natural muscle contractions to adjust its shape and dioptric power on demand, allowing for clear and continuous vision at all distances. By restoring youthful vision, LensGen's technology eliminates the need for reading glasses, offering a significant advancement in the treatment of age-related vision issues.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative treatments for endothelial cell-mediated diseases, particularly focusing on corneal conditions such as Fuchs dystrophy. Utilizing its engineered fibroblast growth factor-1 (FGF-1) technology platform, Trefoil aims to create first-in-class regenerative pharmacologic therapies to address serious ophthalmic diseases that can lead to preventable blindness. The company is currently advancing a topical eye drop formulation, TTHX1114, designed to treat ulcerative conditions affecting the cornea, which can result in corneal scarring and significant vision loss. With a management team possessing over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil is committed to improving human health through protein-engineered therapies. The company has gained recognition within the biopharmaceutical community, receiving accolades from programs such as the CONNECT Springboard business plan competition and the Southeast Biotechnology Early Company Competition.

RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.